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Background
Depression is characterised by negative views of the self.
Antidepressant treatment may remediate negative self-schema
through increasing processing of positive information about the
self. Changes in affective processing during social interactions
may increase expression of prosocial behaviours, improving
interpersonal communications.
Aims
To examine whether acute administration of citalopram is
associated with an increase in positive affective learning biases
about the self and prosocial behaviour.
Method
Healthy volunteers (n = 41) were randomised to either an acute
20 mg dose of citalopram or matched placebo in a between-
subjects double-blind design. Participants completed computer-
based cognitive tasks designed to measure referential affective
processing, social cognition and expression of prosocial
behaviours.
Results
Participants administered citalopram made more cooperative
choices than those administered placebo in a prisoner’s
dilemma task (β = 20%, 95% CI: 2%, 37%). Exploratory analyses
indicated that participants administered citalopram showed
a positive bias when learning social evaluations about a friend
(β = 4.06, 95% CI: 0.88, 7.24), but not about the self or a stranger.
Similarly, exploratory analyses found evidence of increased
recall of positive words and reduced recall of negative words
about others (β = 2.41, 95% CI: 0.89, 3.93), but not the self, in the
citalopram group.
Conclusions
Participants administered citalopram showed greater prosocial
behaviours, increased positive recall and increased positive
learning of social evaluations towards others. The increase in
positive affective bias and prosocial behaviours towards others
may, at least partially, be a mechanism of antidepressant effect.
However, we found no evidence that citalopram influenced self-
referential processing.
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Addressing negative perceptions of the self is believed to be central
to the successful treatment of depression. According to cognitive
theories, individuals with depression hold negative views and expec-
tations about the self, developed as an internalised response to
repeated negative social experiences (e.g. peer victimisation).
When activated by external stressors, these negative self-schema
dominate information processing, increasing automatic processing
of negative information about the self. Deliberative cognitive pro-
cessing is attenuated, preventing reappraisal of these automatic
biases.1 Supportive of this theory, peer victimisation in childhood
is associated with increased negative and reduced positive percep-
tions of the self.2 Furthermore, negative affective biases are more
likely to be observed in depression if stimuli are encoded in refer-
ence to the self.2–5 Changes in self-referential affective processing
may therefore be a key mechanism of treatments for depression.
The role of antidepressants in addressing negative
self-schema
Depression is commonly treated using antidepressant medication.6
Antidepressants are believed to operate by remediating negative
affective biases early in treatment.7 Supportive of this, short-term
administration of antidepressants is associated with increased pro-
cessing of positive stimuli in both depressed and healthy volun-
teers.8 Negative self-schemas may be addressed through these
changes in automatic affective processing.9 Individuals with depres-
sion preferentially process negative information about the self.10
Shifting affective processing through antidepressant treatment
may expose individuals to more positive information about the
self, remediating negative schema. In keeping with this argument,
antidepressants have been found to increase recall of positive char-
acteristics encoded to the self in healthy and depressed
individuals.11,12
Importance of social cognition
In order for changes in affective processing from antidepressant
treatment to alter mood, it has been suggested that individuals
must engage with their social environment to relearn associations
in a more positive context.13 However, this aspect of the model is
yet to be fully explored. Greater depression severity is associated
with poorer-quality social interactions14 and increased expectations
of rejection.15 Raised expectations of rejection may evoke hostile or
non-responsive social behaviours, increasing the likelihood of recip-
rocal negative behaviours from others and reinforcing negative
expectations of social interactions.16,17 In keeping with previous evi-
dence of increases in positive affective biases and behaviours follow-
ing antidepressant administration,11,12,18 antidepressant treatment
is likely to strengthen positive learning and prosocial behaviours
during social interactions. Repeated social interactions with reme-
diated positive affective biases may therefore reinforce engagement
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in future social interactions, potentially addressing the issues of
social withdrawal that are characteristic of depression.
Altering self-schema through changes in social
cognition
The self is a social construct, shaped by our perceptions of others’
evaluations of us.19 During social interactions, healthy individuals
preferentially incorporate positive evaluations into their self-
concept.20 By contrast, individuals with greater depression expect
more negative evaluations,21 selectively engage in negative feed-
back22 and show reduced learning of positive evaluations23 about
the self. Preferential engagement with negative social evaluations
about the self may reinforce negative self-schema and increase
social withdrawal in a vicious cycle. Increasing positive affective
biases through antidepressant treatment may increase learning of
positive social evaluations from others, altering the affective
content of self-schema and breaking the pattern of maladaptive
learning in social interactions. Changes in self-referential affective
learning within social contexts may be an important pathway in
antidepressant action.
Aims
In this study, we examined the influence of acute administration
of citalopram on affective self-referential cognition and social
behaviours in healthy volunteers using a double-blind placebo-
controlled design. We hypothesised that acute administration of
citalopram would be associated with an increase in positive affective
biases about the self and increased prosocial behaviour.
Method
This study was pre-registered on the Open Science Framework
(https://osf.io/nhjvs/), where study materials are also available.
The data that support the findings of this study are openly available
in the University of Bath Research Data Archive at https://doi.org/
10.15125/BATH-00891.
Subjects
Participants aged 18–45 years and fluent in English, with normal or
corrected-to-normal vision, were recruited through advertisement
to the local community. We excluded participants meeting diagnos-
tic criteria for past or current axis 1 DSM-V psychiatric disorder
identified using the Structured Clinical Interview for DSM-V axis
I disorders (SCID-V24). Other exclusion criteria were current use
of psychoactive medication (excluding contraceptive medica-
tion), current or past drug or alcohol dependency, a current or
past significant neurological condition, known hypersensitivity
to the study drug, current pregnancy or breast feeding, current
significant medical condition, consumption of more than five
cigarettes or more than six caffeinated drinks per day, lactose
intolerance, previous participation in a study using similar cogni-
tive tasks, previous participation in a study involving medication
within the past 3 months, or recreational psychoactive drug use
within the past 3 months.
Ethical approval
The authors assert that all procedures contributing to this work
comply with the ethical standards of the relevant national and insti-
tutional committees on human experimentation, and with the
Helsinki Declaration of 1975, as revised in 2008. All procedures
involving human subjects were approved by the University of
Oxford Medical Sciences Interdivisional Research Committee
(R64589). Written informed consent was obtained from all
participants.
Design
This study used a between-subject, double-blind, placebo controlled
design. Participants were randomised to receive a single acute oral
dose of 20 mg citalopram or lactose placebo encapsulated in identi-
cal white capsules. Blocked randomisation, stratified by gender, was
generated using an online randomisation tool.25
Procedure
Participants first completed self-report questionnaires onmood and
personality (baseline) and were administered the study medication.
Citalopram is rapidly absorbed, with peak concentrations reached
within 2–4 h.26 Cognitive testing therefore started following a 3 h
rest period after drug administration, in order to maximise drug
levels during testing. Participants repeated state measures of
mood (post-drug timepoint) and completed the following cognitive
tests in a fixed order: social evaluation learning; associative learning;
prisoner’s dilemma; go/no-go self-esteem; referential categorisation
and recall. Participants then repeated the state measures of mood
(post-testing timepoint), before completing the Oxford Cognition
Stress Task (reported elsewhere). Testing lasted approximately
1.5–2 h. Prior to participating, participants were asked to eat a
light meal and were provided with light refreshments after the
rest period. Participants were informed that the study aimed to
examine how citalopram alters processing of emotional and social
information about the self and others, but they were blinded to
the specific study hypotheses.
Materials
Questionnaires
Depression was measured using the Patient Health Questionnaire
(PHQ-9)27 and Beck Depression Inventory (BDI-II).28 Anxiety
was measured using the Generalised Anxiety Disorder Scale
(GAD-7),29 the Brief Fear of Negative Evaluation Scale30 and the
Trait Anxiety Inventory.31 Personality traits were measured using
the Eysenck Personality Questionnaire Abbreviated.32 State mood
was measured using the State Anxiety Inventory,31 Positive and
Negative Affect Scale (PANAS),33 and visual analogue scales
(VAS) of sadness, disgust, anger, fear, anxiety and alertness. State
mood measures were completed at baseline, post-drug and post-
testing timepoints.
Blinding
To assess the effectiveness of blinding, at the end of testing partici-
pants and the administrating researcher guessed the study drug
administered, and indicated their certainty regarding this guess
using a VAS. Side-effects were also monitored using participant
self-reports of nausea, dizziness, dry mouth, headaches, alertness
and agitation (absent to severe) at each timepoint.
Cognitive tasks
For brevity, a short description of each task is provided below; full
details can be found in the supplementary material, available at
https://doi.org/10.1192/bjo.2020.107.
Prisoners’ dilemma: Antidepressants may promote positive
social relationships with others by increasing prosocial behaviours.
We therefore measured cooperative behaviours using a prisoners’
dilemma task. Participants won points based on their decision to
cooperate or defect in combination with the computer-simulated
opponent’s decision (Fig. 1(a)). If both chose to cooperate then
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the points were equally shared, if one defected and the other coop-
erated then the defector gained all the points, and if both defected
neither player gained any points. Participants were unaware of the
other player’s decision when making their choice. Social context
was manipulated so that the other player could initially choose to
cooperate (positive) or defect (negative). The proportion of
cooperative choices was recorded.
Social evaluation learning: It is possible that antidepressants
may alter negative self-schema by increasing learning of positive
evaluations about the self. We therefore measured learning of
social evaluations within a reinforcement learning task.34,35
Participants learned how much the computer ‘liked’ the self, a
friend and a stranger based on feedback to a forced choice selection
between positive and negative social evaluation pairings (Fig. 1(b)).
Participants learned two rules based on the probability of the posi-
tive evaluations being ‘correct’ (‘like’ 60–80%, ‘dislike’ 20–40%). The
number of errors made before reaching the criterion of eight con-
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Fig. 1 Cognitive task procedures.
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calculated by subtracting errors to criterion made when learning the
dislike rule from the like rule.
Referential categorisation and recall: Previous research has indi-
cated increases in recall of positive characteristics following anti-
depressant administration. However, the specificity of these
effects to the self are unclear. To measure recall of characteristics
about the self and others, participants first categorised whether 40
presented positive and negative traits described themselves or a
familiar other (yes/no). Participants were then given 2 min to
recall those personality traits, using the keyboard to enter their
responses (Fig. 1(c)). Separate blocks were completed for each ref-
erential condition in a randomised order. The total numbers of
words categorised and correctly recalled were recorded.
Self-esteem go/no-go: To measure self-referential processing
occurring in interaction with affective processing we used a go/
no-go task. This task measured inhibitory control when responding
to affective words in relation to the self and others.36 Participants
categorised words relating to the self or others, and positive or nega-
tive traits, by pressing the space bar if a presented word belonged to
a specified paired referential-emotion category (Fig. 1(d)).
Discriminative accuracy (d′) was calculated according to the refer-
ential-emotion condition.
Associative learning: To measure self, emotion and reward
processing occurring independently, we used three simple associa-
tive learning tasks.37,38 In each task, participants were presented
with a combination of stimulus-shape pairings, related to the rele-
vant area of processing, and used the keyboard to indicate
whether the presented pairings matched previously learnt associa-
tions (Fig. 1(e)). Stimuli varied according to the area of processing
examined. Accuracy (percentage correct) and reaction times were
recorded.
Statistical analyses
Analyses were conducted in R 3.6.
Sample size calculation
We aimed to recruit 44 participants to provide 90% power to detect
changes in emotion processing previously observed in healthy vol-
unteer studies (drug mean 10.64 (s.d. 9.77), placebo mean 3.36 (s.d.
5.96)).12 However, owing to COVID-19, recruitment was termi-
nated at 41 participants in March 2020. With the recruited
sample, we were able to detect an effect size of d = 1.04 at 90%
power and an alpha of 0.05.
State mood and side-effects
The influence of citalopram on state mood and side-effects were
tested using mixed-effects linear regression models. Separate
models were conducted for each measure, with drug group, time-
point and the interaction between these as predictors. Participant
was entered as a random effect to account for the effect of time.
Cognitive tasks
A series of mixed-effect linear regression models were used to assess
the influence of citalopram on task performance. For all models,
participant was entered as a random effect to account for the
repeated measures elements of tasks, drug group was entered as a
predictor, and the task outcome as the outcome. For tasks including
a referential and/or valence (e.g. emotion or rule) condition, these
were entered into the models as additional categorical predictors,
independently and in interaction with drug group. Full model
details are available in the supplementary material. For exploratory
analyses, P-values are not reported owing to undetermined inflation
of the alpha rate.39
Drug group guess and certainty
Differences in group assignment guesses according to drug group
were assessed using χ2-tests. Differences in certainty of group
assignment according to drug group were evaluated using t-tests.
Results
Sample
Participants (n = 41) were randomly allocated to the citalopram
(n = 20) or placebo group (n = 21). Sample characteristics, accord-
ing to drug group, are presented in Table 1.
Self-reported state mood
We found no evidence that citalopram altered mood. Participants
showed some evidence of a decrease in positive mood (PANAS posi-
tive) between baseline and post-drug (β =−1.90, 95% CI: −3.77,
−0.02, P = 0.051), and post-testing (β =−2.47, 95% CI: −4.35,
−0.60, P = 0.012), but this did not differ between groups (post-
drug: β =−0.25, 95% CI: −2.84, 2.34, P = 0.852, post-testing:
β =−1.00, 95% CI: −3.59, 1.59, P = 0.450). Participants showed a
slight increase in state anxiety (State-Trait Anxiety Inventory
State Subscale; STAI-S) between baseline and post-testing
(β = 2.31, 95% CI: 0.00, 4.63, P = 0.054), but this did not differ by
drug group (β = 0.64, 95% CI: −2.56, 3.83, P = 0.697). No significant
changes over time or differences between groups were observed for
the PANAS negative subscale or for ratings of disgust, anger, fear,
anxiety or alertness.
Differences were observed between drug groups at baseline in
VAS ratings of happiness and sadness, with the placebo group
Table 1 Sample demographic characteristics and baseline trait mood
and personality self-report measures
Citalopram
(N = 20)a Placebo (N = 21)
Age, mean (s.d.) 23.90 (3.24) 22.86 (3.58)
Female, N (%) 16 (80) 17 (81)
Ethnicity, N (%)
Asian 5 (25) 6 (29)
Black 0 (0) 1 (5)
Caucasian 14 (70) 12 (57)
Mixed 1 (5) 2 (9)
Occupation, N (%)
Employed 5 (25) 4 (19)
Student 15 (75) 17 (81)
Educational attainment, N (%)
Sixth-form college 5 (25) 9 (43)
Undergraduate 7 (33) 7 (33)
Postgraduate 8 (38) 5 (24)
English spoken as first language,
N (%)
10 (50) 19 (90)
PHQ-9, mean (s.d.) 1.05 (1.43) 1.33 (1.93)
BDI-II, mean (s.d.) 1.58 (2.09) 2.24 (3.65)
GAD-7, mean (s.d.) 0.47 (0.70) 0.71 (1.38)
BFNE, mean (s.d.) 26.89 (7.42) 29.57 (6.61)
STAI-T, mean (s.d.) 31.16 (6.32) 32.0 (7.30)
EPQR-A, mean (s.d.)
Extraversion 9.21 (2.42) 9.43 (3.06)
Neuroticism 2.63 (2.50) 3.00 (2.53)
Lie 4.42 (1.89) 4.81 (2.54)
Psychoticism 2.37 (1.83) 2.71 (1.93)
PHQ-9, Patient Health Questionnaire; BDI-II, Beck Depression Inventory II; GAD-7,
Generalised Anxiety Disorder Questionnaire; BFNE, Brief Fear of Negative Evaluation
Scale; STAI-T, State-Trait Anxiety Inventory Trait Subscale; EPQR-A, Eysenck Personality
Questionnaire Abbreviated.
a Data were missing for one participant for mood and personality measures in the cita-
lopram group (N = 19) owing to a technical error.
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showing higher levels of sadness (β = 8.86, 95% CI: 1.50, 16.22, P =
0.021) and lower levels of happiness (β =−8.22, 95% CI: −15.93,
−0.51, P = 0.041). However, exploratory follow-up pairwise com-
parisons of drug group according to timepoint found no group dif-
ferences at future timepoints (Supplementary Table 1).
Cognitive tasks
Prisoner’s dilemma
An effect of the drug was observed on the proportion of cooperative
choices; participants in the placebo group made 20% fewer coopera-
tive choices compared with the citalopram group (95% CI: −37%,
−2%, P = 0.030). There was some suggestion of a main effect of
social context in the expected direction, although the confidence
interval included the null; on average, participants made 13% fewer
cooperative choices when the other player had initially defected
versus cooperated (95% CI: −26%, 1%, P = 0.073). We did not find
evidence of an interaction between drug group and social context,
indicating that participants in the placebo groupmade fewer coopera-
tive choices irrespective of whether the other player initially coopera-
ted or defected (β = 5%, 95% CI: −14%, 24%, P = 0.580; Figure 2).
Social evaluation learning
There were some indications that participants in the citalopram
group showed a greater positive bias overall, as indicated by bias
scores. Participants in the citalopram group, on average, made 4.8
(s.d. 6.64) more errors when learning negative relative to positive
evaluations. By comparison, participants in the placebo group
made 2.25 (s.d. 5.37) more errors on average when learning negative
relative to positive evaluations. This group effect was particularly
heightened for the friend condition (citalopram: −5.70, s.d. 5.45;
placebo: −1.64, s.d. 4.59; Supplementary Fig. 1). However, in our
initial confirmatory model examining main and interaction effects
of the referential condition and drug group, we found no evidence
of group differences (Supplementary Table 2).
To examine whether effects of bias scores were obscured by
learning within a particular rule (e.g. better learning of ‘dislike’ or
worse learning of ‘like’), we examined the effects of drug group on
errors to criterion according to the referential condition and rule.
Participants made a greater number of errors before learning the
negative ‘dislike’ rule (β = 4.53, 95% CI: 2.21, 6.84, P < 0.001).
However, this effect did not vary according to drug group or refer-
ential condition. No main effects of drug, referential condition, or
an interaction between these were observed (Supplementary
Table 2).
Given our previous findings of increased prosocial behaviours
towards others in the citalopram group in the prisoners’ dilemma
task, and given that the sample size may be small for testing inter-
action effects, and that the descriptive statistics suggested a drug
group effect in the friend condition, we conducted additional
exploratory analyses focusing on the effects of drug group in the
friend condition. We therefore examined the effects of drug group
on bias scores separately for each referential condition.
Participants in the citalopram group showed a greater positive
bias in the friend condition (β = 4.06, 95% CI: 0.88, 7.24), but
there was little evidence of a difference between drug groups in
the self (β = 1.95, −2.25, 6.16) or stranger conditions (β = 1.63,
−2.46, 5.72).
To further explore the effect of drug group in the friend condi-
tion, we conducted additional exploratory analyses examining the
effects of rule and drug group on errors to criterion for each refer-
ential condition separately. For the friend condition, an interaction
between drug group and rule was observed (β =−4.06, 95% CI:
−7.14, −0.98). Participants in the citalopram group on average
made 3.55 (s.d. 2.97) errors before learning the ‘like’ rule and 9.25
(s.d. 4.42) errors before learning the ‘dislike’ rule. A smaller differ-
ence was observed between rules for the placebo group, with parti-
cipants on average making 5.19 (s.d. 3.16) errors before learning the
‘like’ rule and 6.38 (s.d. 3.58) errors before learning the ‘dislike’ rule
(Fig. 3). The greater positive bias towards the friend, observed with
bias scores, was therefore driven by both reduced learning of the
friend being disliked and increased learning of the friend being
liked. We found no evidence for an interaction between drug
group and rule when learning about the self (β =−1.95, 95% CI:
−5.73, 1.83) or the stranger (β =−1.63, 95% CI: −5.16, 1.91).
However, these results are exploratory and require further rep-
lication to determine the reliability of the effects.
Referential emotional categorisation and recall
Participants endorsed a greater number of positive words as
descriptive (β =−11.70, 95% CI: −13.50, −9.90, P <0.001), for
both the self and other. There was no evidence that this effect dif-
fered between drug groups (Supplementary Table 3).
When examining the number of correctly recalled words, we
found that participants recalled more positive than negative























Fig. 2 Mean proportion of cooperative behaviours according to drug group and social context. Error bars represent standard deviations.
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weak evidence that this differed according to referential condition,
with participants recalling fewer dislikeable words in the other
versus self condition, although the confidence interval included
the null (β =−1.30, 95% CI: −2.82, 0.22, P = 0.096). We found no
evidence of an interaction between valence and drug group, or ref-
erential condition and drug group (Supplementary Table 3).
There was weak evidence of an interaction between drug group,
referential condition and valence (β = 1.92, 95% CI: −0.20, 4.04, P =
0.079), although the confidence interval included the null. To
explore this effect further, we conducted additional exploratory ana-
lyses examining the interaction between drug group and valence for
each referential condition separately. When recalling words about
the self, participants recalled fewer dislikeable words (β =−1.30,
95% CI: −2.34, −0.27), but this did not vary by drug group
(β = 0.49, 95% CI: −0.96, 1.94). Conversely, when recalling words
about others, we observed an interaction between drug group
and valence (β = 2.41, 95% CI: 0.89, 3.93). Participants in the cita-
lopram group showed a positive bias towards others, recalling more
likeable words and fewer dislikeable words, compared with the
placebo group (Fig. 4). However, these findings are exploratory
and require further replication.
The citalopram group had a higher proportion of participants
that did not speak English as a first language (Table 1), which
may have affected recall. Sensitivity analyses indicated that effects
were consistent when this was taken into account. English as a
first language was not associated with recall (β =−1.13, 95% CI:
−2.48, 0.23, P = 0.112).
Go/no-go self-esteem
Ten participants were excluded from analyses for the go/no-go asso-
ciation self-esteem task as their responses indicated non-compli-
ance according to a priori data exclusion criteria
Participants showed reduced discriminative accuracy for words
relating to others versus self (β =−0.47, 95% CI: −0.84, −0.11,
P = 0.012), and for negative versus positive words (although the
confidence interval included the null; β =−0.36, 95% CI: −0.73,
0.00, P = 0.052). An interaction between referential condition and
valence was observed (β = 0.65, 95% CI: 0.14, 1.16, P = 0.015).
Participants showed higher discriminative accuracy for positive
versus negative words in the self condition, but the opposite
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However, there was no evidence that these effects varied by drug
group (Supplementary Table 4).
Additional analyses suggested that these effects were driven by
hits rather than false alarms (Supplementary Table 4).
When participants excluded according to a priori data exclusion
criteria were included in the sensitivity analyses, the main and inter-
active effects of the referential condition and valence were further
strengthened, but the lack of an effect of drug group remained.
Associative learning
Amain effect of stimuli was observed for the self and emotion tasks,
with participants showing greater accuracy and faster reaction times
when matching shapes with the self and a happy face
(Supplementary Table 5). For the reward task, there was no evidence
of differences in accuracy according to level of reward, although par-
ticipants were slightly slower to match shapes with the medium (£3)
compared with the high (£9) level of reward. There was no evidence
that performance on any of the associative learning tasks varied by
drug group, either as a main effect or in interaction with stimuli
(Supplementary Table 5).
Blinding
A greater proportion of participants in the citalopram group (74%)
believed that they had taken citalopram compared with the placebo
group (14%), at a greater level of certainty (t(30.09) = 3.47, P =
0.002). Conversely, researchers administering the drug did not sig-
nificantly differ in their group guesses and certainty according to
drug group (Supplementary Table 6).
Failure of participant blinding was possibly attributable to the
side-effects of citalopram, with the citalopram group only
showing increases in nausea (P < 0.001) and dizziness (P = 0.012)
over time. An increase in agitation (P = 0.011) and some evidence
of an increase in headaches (P = 0.078) were also observed over
time, but this varied little by group (P = 0.100 and P = 0.474, respect-
ively). There was no evidence of changes for dry mouth or alertness
in either group (Supplementary Table 7).
Discussion
Our results tentatively support the theory that antidepressants
increase positive affective biases and prosocial behaviours in
healthy volunteers, in the absence of change in mood. Participants
administered citalopram cooperated more in a prisoners’ dilemma
game. There was also some evidence, based on exploratory analyses,
that participants administered citalopram showed a greater positive
bias when recalling words about others and when learning social
evaluations about a friend.
In support of our pre-registered hypothesis, participants admi-
nistered citalopram cooperated on a greater proportion of trials in a
prisoners’ dilemma task. Our findings add to the literature indicat-
ing that serotonin is instrumental in modulating social behaviour.
Previous research has indicated that temporary reduction of sero-
tonin through tryptophan depletion reduces cooperative behaviours
in a prisoners’ dilemma game.40 In line with our findings, increasing
serotonin through administration of citalopram over a 2 week
period has previously been found to increase cooperative communi-
cation and behaviour towards others.18 One week administration of
an selective serotonin reuptake inhibitor has also been found to
reduce self-reported hostile behaviours.41 Increases in prosocial
behaviour resulting from antidepressant treatment may increase
quality of social interactions, positively reinforcing engagement in
interpersonal communications and increasing social support.
However, our findings of an increase in cooperative behaviours
following a single dose of citalopram differs from those of previous
research. In a previous study, a single dose of citalopram was not
associated with greater cooperation in healthy volunteers.42
Disagreement between these findings may be attributable to varia-
tions in the prisoners’ dilemma task. In Tse and Bond’s42 study, par-
ticipants controlled the number of points allocated to the other
player. In this study, allocation of points was dependent on both
the participant’s and the other player’s decisions. Prosocial beha-
viours are believed to be motivated by the aim of eliciting reciprocal
altruistic behaviours from others.43 In this study, participants may
have therefore been more motivated to engage in cooperative
actions, providing amore sensitive marker of change following sero-
tonin modulation.
We also found some evidence that antidepressants increase pro-
social affective biases towards familiar others. Participants adminis-
tered citalopram showed better learning of friends being liked and
reduced learning of friends being disliked by a computer persona.
Affective recall was also altered. Participants administered citalo-
pram recalled more likeable characteristics and fewer dislikeable
characteristics of others. However, these were exploratory analyses
and require further replication. One potential mechanism of antide-
pressants may involve blunting perceptions of negative characteris-
tics and increasing sensitivity to positive characteristics in others,
although this requires further exploration in clinical samples.
Increasing positive perceptions of others through antidepressant
treatment may increase engagement in social interactions, thereby
addressing issues of social withdrawal and anhedonia associated
with depression.
In contrast to our expectations, there was no evidence to
support our hypothesis that the effects of antidepressants on affect-
ive processing were strongest for self-referential stimuli. This con-
trasts with previous research indicating a change in positive self-
referential biases following antidepressant administration.11,12
However, in these studies, participants only encoded information
in reference to the self. The specificity of this effect to self-related
information is therefore unclear. In a study including both a self
and friend condition, participants administered escitalopram
endorsed fewer negative characteristics about themselves but also
more positive characteristics about others.44 In this study, we
found no evidence to suggest that citalopram selectively affected
positive learning about the self. If anything, our exploratory analyses
indicated that citalopram produced the largest group effects in the
friend condition, with increased positive learning of social evalua-
tions of friends following antidepressant treatment. However, our
confirmatory test did not support a referential condition by drug
group interaction.
Self-schemas are pervasive, dominate information processing
and are resistant to disconfirmatory evidence.1 A single dose of an
antidepressant may not be sufficient to address entrenched self-ref-
erential negative biases. Affective processing of information related
to others may be more flexible and therefore more sensitive to
change by acute administration of antidepressants. In support of
this theory, pharmacological induction of anxiety was found to
influence other-referential processing, whereas self-referential pro-
cessing was preserved.45 We may therefore only see changes in
self-referential affective biases with longer periods of antidepressant
treatment. Alternatively, addressing negative self-schema may
also require remediation of top-down, deliberative biases through
treatments such as cognitive–behavioural therapy (CBT).9 Further
longitudinal studies are required to examine changes in self-
referential affective biases during long-term use of antidepressants,
to assess their effectiveness in remediating negative self-schema.
We found no evidence that acute citalopram influenced inhibi-
tory control, measured using an affective go/no-go association task,
Effect of citalopram on emotional processing
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or simple associative learning of emotional, self and reward stimuli.
Previous research has reported inconsistent findings regarding the
relationship between depressive symptoms and performance on
affective inhibitory control tasks.46,47 Similarly, we have previously
found no association between simple associative learning and
depression severity.48 Serotonin therefore appears to have little
influence over these particular cognitive processes.
Clinical implications
Variation in individual treatment response and delays in thera-
peutic action currently expose patients to considerable periods of
potentially ineffective antidepressant treatment.49 Our findings
suggest that changes in prosocial behaviours and, more tentatively,
positive affective biases towards others may be sensitive markers of
early changes in response to antidepressant treatment. Extension of
our findings to clinical samples may offer a promising marker of
treatment response that could allow clinicians to identify effective
treatments for individuals experiencing depression at earlier
timepoints.
Limited change in negative self-schema from antidepressant
treatment, as we observed in this study, may provide an explan-
ation for the relatively high relapse rates following treatment
discontinuation.50 At present, it is unclear whether change in
affective processing is sustained after antidepressant treatment
has been discontinued. If increased positive affective biases do
not translate to a sustained change in self-schema, depressive
symptoms are likely to return following antidepressant discon-
tinuation. Sustained changes in self-schema through treatments
such as CBT may explain the substantially lower relapse rates
compared with antidepressant treatment.51
Limitations
This study had lower statistical power than planned, as recruitment
was terminated prematurely owing to COVID-19. We were there-
fore powered to detect large effects and may have been underpow-
ered to detect smaller effects such as the hypothesised interaction
effects for social evaluation learning. To address this limitation,
we have made all materials and data publicly available for further
replication and extension of our work.
In addition, despite strict blinding procedures, there was evi-
dence that blinding was not effective at a participant level. It is pos-
sible that our results may have been partially driven by response
biases. However, mitigating this possibility, we predominantly
used implicit affective tasks, where the main purpose of the tasks
was not explicitly stated, and participants were blinded to the
study hypotheses.
This study used a placebo drug as the comparator condition.
However, high placebo response rates have been observed in
antidepressant trials,52 suggesting that placebo expectations may
influence similar cognitive processes. Future studies including a
no-treatment-control arm condition or a placebo lead-in phase
would allow more precise evaluation of the effects of citalopram
on social cognition.
Finally, this study examined changes in social cognition and
behaviour following antidepressant administration in healthy
volunteers. The use of healthy volunteers offers the opportunity to
study affective biases unconfounded by ‘cold’ cognitive biases.53
However, it limits our insight into the mechanisms of antidepres-
sants in improving mood. It is also possible that our findings may
not directly translate to clinically depressed patients. Further
research would benefit from extending our findings to longer-
term changes in affective processing in depressed individuals.
Summary
Overall, our findings suggest that acute administration of citalo-
pram in healthy volunteers is associated with increased prosocial
behaviour towards others. In contrast to our expectations, we
found little evidence that the effect of acute citalopram on affective
processing was heightened for information related to the self.
Exploratory analyses instead suggested increased positive affective
biases towards others. Changes in affective processing and prosocial
behaviours towards others may, at least partially, be a mechanism of
antidepressant effect. Further research in clinical samples is
required to examine this possibility.
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